NWU Institutional Repository

Epigallocatechin gallate as a nutraceutical to potentially target the metabolic syndrome: novel insights into therapeutic effects beyond its antioxidant and anti-inflammatory properties

dc.contributor.authorNtamo, Yonela
dc.contributor.authorJack, Babalwa
dc.contributor.authorZiqubu, Khanyisani
dc.contributor.authorMazibuko- Mbeje, Sithandiwe E
dc.contributor.authorNkambule, Bongani B
dc.contributor.authorNyambuya, Tawanda M
dc.contributor.authorMabhida, Sihle E
dc.contributor.authorHanser, Sidney
dc.contributor.authorOrlando, Patrick
dc.contributor.authorTiano, Luca
dc.contributor.authorDludla, Phiwayinkosi V
dc.date.accessioned2025-11-24T06:38:10Z
dc.date.issued2024
dc.descriptionJournal Article. Department of Biochemistry, North-West University, Mafikeng
dc.description.abstractEpigallocatechin gallate (EGCG) is one of the most abundant and powerful flavonoids contained in green tea. Because of the global increase in green tea consumption, there has been a general interest in understanding its health benefits, including its bioactive compounds like EGCG. Indeed, preclinical evidence already indicates that EGCG demonstrated a strong antioxidant and anti-inflammatory properties that could be essential in protecting against metabolic syndrome. The current review explores clinical evidence reporting on the beneficial effects of EGCG supplementation in obese subjects or patients with diverse metabolic complications that include type 2 diabetes and cardiovascular disease. The discussion incorporates the impact of different formulations of EGCG, as well as the effective doses and treatment duration. Importantly, besides highlighting the potential use of EGCG as a nutraceutical, the current review also discusses crucial evidence related to its pharmaceutical development as an agent to hinder metabolic diseases, including its bioavailability and metabolism profile, as well as its well-known biological properties.
dc.description.sponsorshipThis work was supported in part by baseline funding from the Biomedical Research and Innovation Platform of the South African Medical Research Council (SAMRC) and the National Research Foundation (NRF) of South Africa (Grant number: 117829). The content hereof is the sole responsibility of the authors and do not necessarily represent the official views of the SAMRC or the funders.
dc.identifier.citationNtamo, Y. et al. 2024. Epigallocatechin gallate as a nutraceutical to potentially target the metabolic syndrome: novel insights into therapeutic effects beyond its antioxidant and anti-inflammatory properties, Critical Reviews in Food Science and Nutrition, 64:1, 87-109. [https://doi.org/10.1080/10408398.2022.2104805]
dc.identifier.issn1040-8398
dc.identifier.urihttp://hdl.handle.net/10394/44201
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.subjectAntioxidants
dc.subjectEpigallocatechin gallate
dc.subjectGreen tea
dc.subjectInflammation
dc.subjectMetabolic syndrome
dc.subjectNutraceuticals
dc.titleEpigallocatechin gallate as a nutraceutical to potentially target the metabolic syndrome: novel insights into therapeutic effects beyond its antioxidant and anti-inflammatory properties
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ntamo, Y. et al. 2024.pdf
Size:
5.32 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections